Inflammation and microbiota fingerprint: Delphi's oracle for NAFLD-related HCC? by Cassano, Marco & Dufour, Jean-François
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1002/hep.30267 
This article is protected by copyright. All rights reserved. 
Article type      : Editorial 
 
Corresponding Author Email ID: jean-francois.dufour@insel.ch 
 
Inflammation and microbiota fingerprint: Delphi’s oracle for NAFLD-related HCC? 
 
Marco Cassano1 and Jean-François Dufour2,3  
 
1School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL)Lausanne, 
Switzerland 
2University Clinic for Visceral Surgery and Medicine, Inselspital, University of Berne, 
Switzerland 
3Department of Biomedical Research, University of Berne, Switzerland 
 
Dysfunctions of the gut bacterial flora have an important impact on liver diseases. Quantitative 
or qualitative ruptures of intestinal homeostasis, collectively termed dysbiosis, constitute an 
increasingly recognized associated factor for chronic liver diseases, including non-alcoholic 
fatty liver disease (NAFLD). The evidence that gut maladaptation is a common feature in NAFLD 
settings led Ponziani et al. to investigate whether specific variations of the flora and 
inflammatory cues are enriched in NAFLD patients presenting with HCC (Ponziani et al. this 
issue). The authors included prospectively 21 patients with NAFLD-related cirrhosis and HCC, 
20 patients with NAFLD-related cirrhosis without HCC and 20 healthy controls. In addition to 
age, cirrhotic’s cohorts were also matched on severity of liver disease and portal hypertension. 
While observing similar dysfunctions of gut permeability within cirrhotic patients, the authors 
reported an increased intestinal-derived permeability in cirrhotic subjects with HCC, revealed 
by the increase in lipopolysaccharides and zonulin-1 plasma level compared to healthy control. 
The pattern of cytokines further supports an inflammatory milieu specific of cirrhotic patients 
with and without HCC. Myeloid-derived suppressor cells (mMDSC), which are bone marrow-
derived cells whose diagnostic and prognostic significance has been recently reported in HCC 
patients, are thought to promote tumor progression primarily by suppressing the antitumor 
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immunity and favoring tumor angiogenesis (1). Ponziani et al. found that pro-inflammatory 
mediators such as IL8, IL13, CCL3, CCL4, and CCL5 were significantly increased in the presence 
of HCC and positively correlated with the levels of circulating activated monocytes and 
monocytic MDSC (figure 1).  
 
When Ponziani and colleagues performed the 16S RNA-based metagenomic analysis of 
the gut microbial composition they found cirrhotic patients to have a lower gut microbial 
diversity compared to controls, independent of the presence of HCC. The authors suggest a 
framework where cirrhosis affects the gut microbial composition. According to their results, the 
dysbiotic fingerprint of the whole cirrhotic cohort (with and without HCC) is characterized by 
alterations of specific bacterial genera, as defined by the relative abundance in 
Enterobacteriaceae, Streptococcus, Bacteroides, and Ruminococcus among others, and the 
reduction in Bifidobacterium and Akkermansia.  
 
The authors proposed that the reduction of specific bacterial genera such as 
Akkermansia and Bifidobacterium sensitizes the inflammatory risks of NAFLD patients and 
correlate with increased CCL5 and calprotectin levels. Importantly, Ponziani et al. have shown 
unappreciated taxonomic differences when comparing the microbiota of cirrhotic patients with 
or without HCC, such as the increased abundance of Bacteroides and Ruminococcaceae, 
potentially spurring disease progression via pro-tumorigenic cues. 
 
Studies point out that hepato-metabolic disease risk involves multiple strains of bacteria 
and since the gut flora composition can differ from person to person, it means that single 
bacterial species might not explain the full responsibility of the disease. A promising strategy 
might be to promote the growth of healthy bacterial strains rather than target the bad ones. 
This is supported by some early clinical evidence that specially formulated probiotics (cocktails 
of “good” bacteria) can bump the microbiome back into balance (2, 3). It is still early days for 
this research, but the premises are exciting since almost 30% of the metabolites in the blood are 
accountable by from intestinal bacteria. 
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This study advances our knowledge of intestine-derived inflammation and HCC.  The 
authors define a specific set of inflammatory regulators such as CCL3, CCL4, and CCL5 
associated with cirrhosis and HCC. They also highlight the clinical significance of correlating 
cytokine/chemokine profile with the recruitment of cellular infiltrates hastening tumor 
progression via immunosuppressive effects. Their findings corroborate previous studies 
defining the pro-tumorigenic role of these cytokines in both animal models and clinical settings 
(4-7). These observations follow on previous seminal studies performed with similarities and 
also remarkable differences both in terms of study design and operational procedures. 
Exploiting a quantitative-metagenomic based resource Qin and colleagues compared the gut-
metagenomic signature of 98 Chinese patients with cirrhosis predominantly due to viral 
hepatitis and alcoholic cirrhosis with 83 healthy controls, finding an enrichment of taxonomical 
species of buccal origin, indicative of an invasion of the gut from the mouth in liver cirrhosis (8). 
Further, Bajaj and coworkers characterized the association of gut microbiome with hepatic 
decompensation in 219 cirrhotic patients, although 17% of patients presented with NAFLD-
related conditions and only 68% were of Caucasian origin precluding comparison with the 
study of Ponziani et al. (9). Loomba and colleagues integrated stool metagenomic profiling with 
the assessment of serum analytes via metabolomics in 86 patients with biopsy-proven NAFLD 
to examine the diagnostic potential of microbiome-derived signature for the presence of 
advanced fibrosis (10). All these studies recorded changes in the gut microbiota of patients with 
different states known to predispose to liver diseases. 
 
Additionally, dysbiosis seems to associate with an increase in the size of the population 
of bacteria that produce ethanol. So, although the name NAFLD contains the term ‘non-
alcoholic’, the reality of the condition is more complicated and alcohol from bacteria may still 
play a part in its origins. An alluring and so far unexplored frame prompted by Ponziani et al. 
might come from the correlation of the phenotypic severity with the deregulation of ethanol-
producing bacterial population.  
 
The generalizability of the results of Ponziani et al. is uncertain since this is a single 
center study with a relatively small cohort size. Their cohort selection followed tight selection 
criteria, ethnicity and diet amongst many others, aimed to minimize the impact of these 
confounding factors tough such stringency may also limit the holistic interpretation of microbial 
composition’s shifts. Nevertheless, the contribution of this work elegantly corroborates the 
compelling evidence of a link between inflammation, changes in the gut microbiota composition 
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and NAFLD-related cirrhosis and HCC. The details and relative importance of the proposed 
mechanisms by which dysbiosis causes liver damage via inflammation are still unclear. The 
intestinal microbiota profiling has not yet provided a clear causative relationship between 
dysbiosis and HCC development. Still, the potential of microbiome-based metagenomic 
signatures is enormous and interventions to prevent this dreadful disease warrant further 
studies to pin down the importance of these associations.  
 
This work sets the stage to a new way of monitoring and preventing liver cirrhosis, 
indicating that stool- and plasma-based test may represent a powerful diagnostic tool for 
disease detection, adjunctive or more optimistically substitutive to current invasive approaches 
for staging liver diseases. It is plausible that the serum/plasma based tests, as the cytokine 
analysis performed by the authors, may be used in conjunction with the bacterial metagenomic 
signature to elevate the non-invasive screening potential of detecting advanced fibrosis, 
cirrhosis and ultimately HCC risk.  
 
Legend Figure 1. The presence of a hepatocellular carcinoma in patients with cirrhosis due to 
non-alcoholic fatty liver disease is associated with changes in the gut and in the blood 
compartments. In the gut, the authors report an increased intestinal permeability, increased 
levels of fecal calprotectin and modifications in the composition of the microbiome. In the blood, 
they found increased levels of pro-inflammatory mediators such as interleukin 8 and 13 and C-C 
motif chemokine ligand 3, 4 and 5. 
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Figure 1. 
  
